{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:57:26Z","timestamp":1772103446596,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.yexcr.2026.114941","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:59:21Z","timestamp":1770911961000},"page":"114941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["p300-mediated acetylation of KCNN4 drives enzalutamide resistance in prostate cancer"],"prefix":"10.1016","volume":"457","author":[{"given":"Weiqiang","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiankun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zekun","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2026.114941_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107932","article-title":"Prostate cancer biomarkers: from diagnosis to prognosis and precision-guided therapeutics","volume":"228","author":"Adamaki","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.yexcr.2026.114941_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrc3678","article-title":"Maintaining and reprogramming genomic androgen receptor activity in prostate cancer","volume":"14","author":"Mills","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.yexcr.2026.114941_bib3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/cac2.12340","article-title":"Treatment intensification for metastatic prostate cancer: new treatment landscapes in androgen deprivation-based therapy","volume":"42","author":"Turco","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"10442","key":"10.1016\/j.yexcr.2026.114941_bib4","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(24)00802-X","article-title":"Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer management","volume":"403","author":"Pollack","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.yexcr.2026.114941_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2010.136","article-title":"Drug resistance in metastatic castration-resistant prostate cancer","volume":"8","author":"Seruga","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.114941_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad","year":"2015","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.yexcr.2026.114941_bib7","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/cr.2010.121","article-title":"Migration-associated secretion of melanoma inhibitory activity at the cell rear is supported by KCa3.1 potassium channels","volume":"20","author":"Schmidt","year":"2010","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.yexcr.2026.114941_bib8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1182\/blood-2015-07-657957","article-title":"Mutations in the Gardos channel (KCNN4) are associated with hereditary xerocytosis","volume":"126","author":"Glogowska","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.yexcr.2026.114941_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.molcel.2016.06.021","article-title":"Identification of PGAM5 as a mammalian protein histidine phosphatase that plays a central role to negatively regulate CD4(+) T cells","volume":"63","author":"Panda","year":"2016","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.yexcr.2026.114941_bib10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-022-00891-0","article-title":"Dextran sodium sulfate potentiates NLRP3 inflammasome activation by modulating the KCa3.1 potassium channel in a mouse model of colitis","volume":"19","author":"Zeng","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"11","key":"10.1016\/j.yexcr.2026.114941_bib11","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1136\/gutjnl-2018-317479","article-title":"GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner","volume":"68","author":"Jiang","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.yexcr.2026.114941_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12951-024-02827-4","article-title":"ACYP2 functions as an innovative nano-therapeutic target to impede the progression of hepatocellular carcinoma by inhibiting the activity of TERT and the KCNN4\/ERK pathway","volume":"22","author":"Wu","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.yexcr.2026.114941_bib13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41401-021-00688-3","article-title":"KCNN4-mediated Ca(2+)\/MET\/AKT axis is promising for targeted therapy of pancreatic ductal adenocarcinoma","volume":"43","author":"Mo","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.yexcr.2026.114941_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12935-022-02626-7","article-title":"KCNN4 may weaken anti-tumor immune response via raising Tregs and diminishing resting mast cells in clear cell renal cell carcinoma","volume":"22","author":"Cui","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"4","key":"10.1016\/j.yexcr.2026.114941_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/cr.2007.10","article-title":"Roles of CREB-binding protein (CBP)\/p300 in respiratory epithelium tumorigenesis","volume":"17","author":"Karamouzis","year":"2007","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.yexcr.2026.114941_bib16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0168-9525(98)01438-3","article-title":"Conjunction dysfunction: CBP\/p300 in human disease","volume":"14","author":"Giles","year":"1998","journal-title":"Trends Genet."},{"issue":"15","key":"10.1016\/j.yexcr.2026.114941_bib17","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/0008-5472.CAN-20-0233","article-title":"p300-Mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer","volume":"80","author":"Xu","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2026.114941_bib18","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c01100","article-title":"Discovery of a highly potent PROTAC degrader of p300\/CBP proteins for the treatment of enzalutamide-resistant prostate cancer","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.yexcr.2026.114941_bib19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jcp.25099","article-title":"Androgen receptor coactivators in regulation of growth and differentiation in prostate cancer","volume":"231","author":"Culig","year":"2016","journal-title":"J. Cell. Physiol."},{"issue":"20","key":"10.1016\/j.yexcr.2026.114941_bib20","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1158\/0008-5472.CAN-17-0314","article-title":"Therapeutic targeting of the CBP\/p300 bromodomain blocks the growth of castration-resistant prostate cancer","volume":"77","author":"Jin","year":"2017","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.yexcr.2026.114941_bib21","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/1078-0432.CCR-20-4391","article-title":"Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells","volume":"27","author":"Pan","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.yexcr.2026.114941_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/ERC-19-0488","article-title":"p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer","volume":"27","author":"Gruber","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.yexcr.2026.114941_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-121211-091605","article-title":"Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer","volume":"64","author":"Ferraldeschi","year":"2013","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.yexcr.2026.114941_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-022-01236-z","article-title":"Discovery of C19-9 as a novel non-RGD inhibitor of alphavbeta3 to overcome enzalutamide resistance in castration-resistant prostate cancer","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.yexcr.2026.114941_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41392-023-01720-0","article-title":"Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"5","key":"10.1016\/j.yexcr.2026.114941_bib26","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:58:49Z","timestamp":1772099929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482726000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0014482726000583"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.114941","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p300-mediated acetylation of KCNN4 drives enzalutamide resistance in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.114941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114941"}}